Different effects of gemcitabine + paclitaxel and gemcitabine +oxaliplatin chemotherapy on the malignant biology of advanced bladder cancer

摘要

Objective: To explore the different effects of gemcitabine + paclitaxel and gemcitabine +oxaliplatin chemotherapy on the malignant biology of advanced bladder cancer. Methods: A total of 109 patients with advanced bladder cancer who were treated in the hospital between June 2014 and January 2017 were retrospectively analyzed and then divided into paclitaxel group (n=52) and oxaliplatin group (n=57). Paclitaxel group received gemcitabine + paclitaxel therapy, and oxaliplatin group received gemcitabine + oxaliplatin therapy. The differences in the expression of proliferation, invasion and autophagy genes in the urine were compared between the two groups before and after treatment. Results: Before treatment, there was no statistically significant difference in the expression of proliferation, invasion and autophagy genes in the urine between the two groups. After treatment, proliferation genes ABCE1 and YAP mRNA expression in the urine of paclitaxel group were lower than those of oxaliplatin group while MTSS1 mRNA expression was higher than that of oxaliplatin group; invasion genes CBX7 and NDRG2 mRNA expression were higher than those of oxaliplatin group while ILK, KPNA2 and SPOCK1 mRNA expression were lower than those of oxaliplatin group;autophagy gene LC3 mRNA expression was lower than that of oxaliplatin group while Beclin1 mRNA expression was higher than that of oxaliplatin group. Conclusion: Gemcitabine +paclitaxel chemotherapy may be more effective in inhibiting the malignant biological behavior of tumor cells in patients with advanced bladder cancer.